Allergan turns down Valeant

Share this article:

Allergan's board has told Valeant to take its takeover offer elsewhere. Modern Healthcare reports that Allergan's board said the $54 million offer was too low, with too much shareholder risk.

CEO David Pyott told MH the fallout would have probably included a reduced R&D budget, less advertising and higher prices for Allergan products.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.